FOURIER Clinical Trial - Evolocumab and Clinical Outcomes in Patients…
NEJM on Twitter: "Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER) https://t.co/XorSjqmvoy #ACC17 https://t.co/wzFxrdlbzn" / Twitter
Repatha® Clinical Trials | Repatha® (evolocumab)
Menu search Login Register English Login Register Director Deputy for Aministrative Affairs Main page Finance management Management of Administrative Affairs Director of the budget and organization IT management Deputy for Research Affairs Main ...
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization | Journal of the American College of Cardiology
Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER | Circulation
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies | Circulation
PDF) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease Marc S. Sabatine, M.D., M.P.H., Robert P. Giugliano, M.D., Anthony C. Keech, M.D., Narimon Honarpour, M.D., Ph.D., Stephen D. Wiviott, M.D., Sabina
Managed Care Pharmacist Updates for Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) Inhibitors
![PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/993698ddc1fcdfd3e66edebf1904b360eca3b4a8/4-Table1-1.png "PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar")
PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar
![PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/993698ddc1fcdfd3e66edebf1904b360eca3b4a8/6-Table2-1.png "PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar")
PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar
![PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/993698ddc1fcdfd3e66edebf1904b360eca3b4a8/7-Figure2-1.png "PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar")
PDF] Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Semantic Scholar
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl | PLOS ONE
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial - ScienceDirect
FOURIER (TIMI 59) / EBBINGHAUS – TIMI STUDY GROUP
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) | Journal of the American College of Cardiology
PDF) Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER
PCSK9 inhibitors in clinical practice: Delivering on the promise? - Atherosclerosis
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | NEJM
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia | Journal of the American College of Cardiology
Frontiers | PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects | Physiology
FOURIER Clinical Trial - Evolocumab and Clinical Outcomes in Patients…
